tucatinib,trastuzumab deruxtecan
seagen,astrazeneca,daiichi sankyo
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'tuca ', 'tdxd', 't-dxd']
tdxd highly effective in her2 ihc 3+ mss mcrc orr 46.9%
no activity in ihc2+/ish+ orr 5.6% where is the bystander effect also, tdxd effective in previously treated with anti-her2 trastu-tuca in ihc2+/ish+,orr 20% what about gene copy number?
#wcgic2023 
MD Medical Oncology 👨🏼‍⚕🦀🏥 // University Hospital of Salamanca. #FerrolMola #OrgulloGalego